Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study - PubMed (original) (raw)

Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study

Andrew P Prayle et al. BMJ. 2012.

Free article

Abstract

Objective: To examine compliance with mandatory reporting of summary clinical trial results (within one year of completion of trial) on ClinicalTrials.gov for studies that fall under the recent Food and Drug Administration Amendments Act (FDAAA) legislation.

Design: Registry based study of clinical trial summaries.

Data sources: ClinicalTrials.gov, searched on 19 January 2011, with cross referencing with Drugs@FDA to determine for which trials mandatory reporting was required within one year. Selection criteria Studies registered on ClinicalTrials.gov with US sites which completed between 1 January and 31 December 2009.

Main outcome measure: Proportion of trials for which results had been reported.

Results: The ClinicalTrials.gov registry contained 83,579 entries for interventional trials, of which 5642 were completed within the timescale of interest. We identified trials as falling within the mandatory reporting rules if they were covered by the FDAAA (trials of a drug, device, or biological agent, which have at least one US site, and are of phase II or later) and if they investigated a drug that already had approval from the Food and Drug Administration. Of these, 163/738 (22%) had reported results within one year of completion of the trial compared with 76/727 (10%) trials that were not subject to mandatory reporting (95% confidence interval for the difference in proportions 7.8% to 15.5%; χ(2) test, P = 2.6 × 10(-9)). Later phase trials were more likely to report results (P = 4.4 × 10(-11)), as were industry funded trials (P = 2.2 × 10(-16)).

Conclusion: Most trials subject to mandatory reporting did not report results within a year of completion.

PubMed Disclaimer

Cited by

Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.gov: a cross-sectional study.
Šaler F, Viđak M, Puljak L. Šaler F, et al. BMC Med Res Methodol. 2024 Jul 30;24(1):164. doi: 10.1186/s12874-024-02292-5. BMC Med Res Methodol. 2024. PMID: 39080564 Free PMC article.
Predicting drug outcome of population via clinical knowledge graph.
Brbić M, Yasunaga M, Agarwal P, Leskovec J. Brbić M, et al. medRxiv [Preprint]. 2024 Oct 19:2024.03.06.24303800. doi: 10.1101/2024.03.06.24303800. medRxiv. 2024. PMID: 38496488 Free PMC article. Preprint.
Chinese Clinical Trial Registry 13-year data collection and analysis: geographic distribution, financial support, research phase, duration, and disease categories.
Fan R, Zheng Y, Zhou R, Beeraka NM, Sukocheva OA, Zhao R, Li S, Zhao X, Liu C, He S, Mahesh PA, Gurupadayya BM, Nikolenko VN, Zhao D, Liu J. Fan R, et al. Front Med (Lausanne). 2023 Oct 12;10:1203346. doi: 10.3389/fmed.2023.1203346. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37901406 Free PMC article.
Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis.
Yao P, Zhang Y, Zhang S, Wei X, Liu Y, Du C, Hu M, Feng C, Li J, Zhao F, Li C, Li Z, Du L. Yao P, et al. Front Oncol. 2023 Jan 5;12:1039882. doi: 10.3389/fonc.2022.1039882. eCollection 2022. Front Oncol. 2023. PMID: 36686767 Free PMC article.
Is there resource wastage in the research for spinal diseases? An observational analysis of discontinuation and non-publication in randomised controlled trials.
Demetriades AK, Park JJ, Tiefenbach J. Demetriades AK, et al. Brain Spine. 2022 Aug 6;2:100922. doi: 10.1016/j.bas.2022.100922. eCollection 2022. Brain Spine. 2022. PMID: 36248143 Free PMC article.

Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study - PubMed (original) (raw)